Where's the evidence? A systematic review exploring the evidence underpinning exercise dose in clinical trials of rheumatoid arthritis

Physiotherapy ◽  
2021 ◽  
Vol 113 ◽  
pp. e16-e17
Author(s):  
G. Boniface ◽  
V. Gandhi ◽  
M. Norris ◽  
E. Williamson ◽  
S. Kirtley ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systematic Review ◽  
Clinical Trials ◽  
Exercise Dose

scholarly journals Bee venom acupuncture for rheumatoid arthritis: a systematic review of randomised clinical trials

BMJ Open ◽  
2014 ◽  
Vol 4 (11) ◽  
pp. e006140 ◽  
Author(s):  
Ju Ah Lee ◽  
Mi Ju Son ◽  
Jiae Choi ◽  
Ji Hee Jun ◽  
Jong-In Kim ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systematic Review ◽  
Clinical Trials ◽  
Bee Venom ◽  
Randomised Clinical Trials ◽  
Bee Venom Acupuncture

scholarly journals Adalimumab in rheumatoid arthritis treatment: a systematic review and meta-analysis of randomized clinical trials

2013 ◽  
Vol 53 (5) ◽  
pp. 419-430
Author(s):  
Marina Amaral de Ávila Machado ◽  
Alessandra Almeida Maciel ◽  
Lívia Lovato Pires de Lemos ◽  
Juliana Oliveira Costa ◽  
Adriana Maria Kakehasi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systematic Review ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Rheumatoid Arthritis Treatment

scholarly journals Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage

2020 ◽  
Vol 12 ◽  
pp. 1759720X2095997
Author(s):  
Julien Blaess ◽  
Julia Walther ◽  
Arthur Petitdemange ◽  
Jacques-Eric Gottenberg ◽  
Jean Sibilia ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systematic Review ◽  
Clinical Trials ◽  
Immunosuppressive Agents ◽  
Development Stage ◽  
Clinical Development ◽  
Phase Iii ◽  
Current Development ◽  
To Come ◽  
New Treatments

Aims: With the arrival of conventional synthetic (csDMARDs), biological (bDMARDS) and then targeted synthetic (tsDMARDs) disease-modifying anti-rheumatic drugs, the therapeutic arsenal against rheumatoid arthritis (RA) has recently expanded. However, there are still some unmet needs for patients who do not achieve remission and continue to worsen despite treatments. Of note, most randomized controlled trials show that, for methotrexate-inadequate responders, only 20% of patients are ACR70 responders. With our better understanding of RA pathogenesis, finding new treatments is a necessary challenge. The objective of our study was to analyse the whole pipeline of immunosuppressive and immunomodulating drugs evaluated in RA and describe their mechanisms of action and stage of clinical development. Methods: We conducted a systematic review of all drugs in clinical development in RA, in 17 online registries of clinical trials. Results: The search yielded 4652 trials, from which we identified 243 molecules. Those molecules belong to csDMARDs ( n = 22), bDMARDs ( n = 118), tsDMARDs ( n = 103). Twenty-four molecules are already marketed in RA in at least one country: eight csDMARDs, 10 bDMARDs and six tsDMARDs. Molecules under current development are mainly bDMARDs ( n = 34) and tsDMARDs ( n = 33). Seven of those have reached phase III. A large number of molecules (150/243, 61.7%) have been withdrawn. Conclusion: Despite the availability of 24 marketed molecules, the development of new targeted molecules is ongoing with a total of 243 molecules in RA. With seven molecules currently reaching phase III, we can expect an increase in the armamentarium in the years to come.

scholarly journals Erratum of “Adalimumab in rheumatoid arthritis treatments: a systematic review and meta-analysis of randomized clinical trials”

2014 ◽  
Vol 54 (2) ◽  
pp. 160
Author(s):  
Marina Amaral de Ávila Machado ◽  
Alessandra Almeida Maciel ◽  
Lívia Lovato Pires de Lemos ◽  
Juliana Oliveira Costa ◽  
Adriana Maria Kakehasi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systematic Review ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Meta Analysis

scholarly journals Low level laser therapy for reducing pain in rheumatoid arthritis and osteoarthritis: a systematic review

2019 ◽  
Vol 32 ◽  
Author(s):  
Renan Fangel ◽  
Leticia Meda Vendrusculo-Fangel ◽  
Cleandro Pires de Albuquerque ◽  
Nivaldo Antônio Parizotto ◽  
Clarissa Cardoso dos Santos C. Paz ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systematic Review ◽  
Clinical Trials ◽  
Laser Therapy ◽  
Low Level Laser Therapy ◽  
Low Level ◽  
Low Level Laser ◽  
Mesh Terms ◽  
Level Laser ◽  
Patient Studies

Abstract Introduction: Treatments for rheumatoid arthritis (RA) and osteoarthritis (OA) can reduce, modulate inflammation, and reduce deformities. Low-Level Laser Therapy is a biomodulator and may aid in the clinical picture of these conditions. Objective: To analyze the parameters most frequently used to determine the responses of patients with RA and OA in controlled and uncontrolled clinical trials. Method: This is a systematic review with search of articles in English, Portuguese and Spanish in PUBMED, SCOPUS, LILACS and Web of SCIENCE, of articles published between 2006 and 2018. MeSH terms were used. Inclusion criteria: evaluation of LLLT in the evaluations, evaluation and evaluation of the period, controlled and uncontrolled clinical trials, full publications. The base date of the energy dosimetry and the analysis of mean, median and mode of energy per point and energy per treatment. Results: Three articles on RA and 16 on OA were included in this study. Regarding dosimetry, it was one of the most recent of the pain, being this one with a greater energy dose. In OA, most of the articles presented are of importance, with variability in the dosage applied. Conclusion: There are several reports for patient studies purposes, mainly with doses of 6 J per point and 48 J. In the joints affected with OA and AR, it would be important to publish more scientific articles with better methodological quality and description of dosimetry.

Sign in / Sign up

Export Citation Format

Share Document